Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...

Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that could adversely impact its business and financial ...

Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by ...

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a ...

Shares of IGM Biosciences were falling sharply Tuesday after the biotechnology company announced “a strategic pivot and ...

IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from oncology to a focus on autoimmune diseases, with at least two opting to ...

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) fell sharply in today's pre-market trading after the company announced plans to focus exclusively on autoimmunity and named Beth Harler as CEO.

WINNIPEG, MB , Nov. 5, 2024 /CNW/ - IGM Financial Inc. (IGM) (TSX: IGM) today reported total assets under management and advisement of $264.8 billion at October 31, 2024 , up 18.0% from $224.4 billion ...

英为财情Investing.com - IGM Biosciences (NASDAQ: IGMS)星期五发布了第三季度的财报，数据显示，公司营收高于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The wait for light and sound show at Brahma Sarovar is getting longer.During the last International Gita Mahotsav (IGM), the ...